Seyed Amin Mousavi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Seyed Amin Mousavi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Morteza Amestejani
Department of General Surgery, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
2 shared publications - Souzan Soufizadeh Balaneji
Department of Obstetrics and Gynecology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
2 shared publications - Abdolrasoul Talei
Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Alireza Golchini
General Medical Council, London, United Kingdom
1 shared publication - Aliyeh Ranjbar
Breast Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
1 shared publication Ehsan Kafili
Department of Surgery, Imam Khomeini Hospital, University of Medical Sciences, Urmia, Iran
1 shared publication
Latest Publications
- Open Access
- 1 July 2025
- Published by Maad Rayan Publishing Company in hormozgan medical journal
- Vol. 29 (3) , 154-157
Neuroendocrine Cancer of the Breast: The Report of a Rare but Challenging Entity
Background: Neuroendocrine breast cancer (NEBC) is a rare subtype of breast cancer, accounting for a very small proportion of all breast cancer cases. Case Presentation: A 41-year-old nonsmoking woman presented with a two-month history of a right breast lump. She had no significant medical or family history of cancer. Mammography showed an abnormal mass with jagged margins located in the upper outer quadrant of the right breast. Subsequent tests with ultrasound demonstrated a complex, dark mass measuring about 2.5×1.8 cm, located 3 cm from her right nipple. Conclusion: Microscopic examination of the excised tissue demonstrated a grade 3 primary neuroendocrine carcinoma of the breast. This is a serious type of cancer. Further tests showed that the cancer cells were sensitive to estrogen and progesterone hormones but negative for HER2, confirming the diagnosis of neuroendocrine breast cancer. After surgery, the patient received additional treatments such as chemotherapy, radiotherapy, and oral tamoxifen.
- 1 July 2025
- Published by Maad Rayan Publishing Company in hormozgan medical journal
- Vol. 29 (3) , 154-157
Open AccessNeuroendocrine Cancer of the Breast: The Report of a Rare but Challenging Entity
Background: Neuroendocrine breast cancer (NEBC) is a rare subtype of breast cancer, accounting for a very small proportion of all breast cancer cases. Case Presentation: A 41-year-old nonsmoking woman presented with a two-month history of a right breast lump. She had no significant medical or family history of cancer. Mammography showed an abnormal mass with jagged margins located in the upper outer quadrant of the right breast. Subsequent tests with ultrasound demonstrated a complex, dark mass measuring about 2.5×1.8 cm, located 3 cm from her right nipple. Conclusion: Microscopic examination of the excised tissue demonstrated a grade 3 primary neuroendocrine carcinoma of the breast. This is a serious type of cancer. Further tests showed that the cancer cells were sensitive to estrogen and progesterone hormones but negative for HER2, confirming the diagnosis of neuroendocrine breast cancer. After surgery, the patient received additional treatments such as chemotherapy, radiotherapy, and oral tamoxifen.
- 6 May 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 97 (4) , 35-43
The effectiveness of local steroid injection for the treatment of breast-limited idiopathic granulomatous mastitis: A randomized controlled clinical trial study
Introduction: Idiopathic granulomatous mastitis (IGM) is a rare, non-specific inflammatory breast disease. There are severalcontroversies regarding its standard treatment.Aim: We aimed to evaluate the efficacy of local corticosteroid injection compared to systemic steroids and combined treatment of both in IGM patients.Methods: In this randomized controlled clinical trial study, 115 IGM patients were randomly allocated to three groups of localsteroid injection (Betamethasone, n = 37), systemic steroid treatment (Prednisolone + MTX, n = 37), or combined treatment ofboth (n = 41) for a follow-up period of 10 months. Clinical presentations and outcomes were compared between the groups.Results: The mean age of the study patients was 35.6 years. The mean time to complete remission was 3.17, 4.33, and 6.37 months, and the relapse rate during the treatment was 0%, 5.26%, and 13.33% in the injection, combined, and systemic therapy groups, respectively. There was no significant difference between the clinical response to treatment rate and the recurrence rate during the follow-up between the groups. Four patients in the combined therapy group and 3 patients in the systemic therapy group had steroid side effects, with no side effects in the injection group.Conclusions: Steroid injection therapy is more effective than combined therapy and systemic therapy in terms of remission and relapse rate during the treatment, and is as effective as systemic therapy in the clinical response to treatment rate and the recurrence rate during the follow-up period. Regarding the lack of side effects of the steroid injection therapy, this approach could be considered among the first-line treatment options.
- 6 May 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 97 (4) , 35-43
The effectiveness of local steroid injection for the treatment of breast-limited idiopathic granulomatous mastitis: A randomized controlled clinical trial study
Introduction: Idiopathic granulomatous mastitis (IGM) is a rare, non-specific inflammatory breast disease. There are severalcontroversies regarding its standard treatment.Aim: We aimed to evaluate the efficacy of local corticosteroid injection compared to systemic steroids and combined treatment of both in IGM patients.Methods: In this randomized controlled clinical trial study, 115 IGM patients were randomly allocated to three groups of localsteroid injection (Betamethasone, n = 37), systemic steroid treatment (Prednisolone + MTX, n = 37), or combined treatment ofboth (n = 41) for a follow-up period of 10 months. Clinical presentations and outcomes were compared between the groups.Results: The mean age of the study patients was 35.6 years. The mean time to complete remission was 3.17, 4.33, and 6.37 months, and the relapse rate during the treatment was 0%, 5.26%, and 13.33% in the injection, combined, and systemic therapy groups, respectively. There was no significant difference between the clinical response to treatment rate and the recurrence rate during the follow-up between the groups. Four patients in the combined therapy group and 3 patients in the systemic therapy group had steroid side effects, with no side effects in the injection group.Conclusions: Steroid injection therapy is more effective than combined therapy and systemic therapy in terms of remission and relapse rate during the treatment, and is as effective as systemic therapy in the clinical response to treatment rate and the recurrence rate during the follow-up period. Regarding the lack of side effects of the steroid injection therapy, this approach could be considered among the first-line treatment options.
- Open Access
- 30 December 2021
- Published by SAGE Publications in Surgical Innovation
- Vol. 29 (6) , 742-746
The Association of Vitamin D3 With Early Anastomotic Leakage in Patients Undergoing Hemicolectomy Surgery
Anastomotic leak (AL) is one of the most important postoperative complications after hemicolectomy with stapled anastomosis. This study aimed to evaluate the association of preoperative vitamin D3 with early anastomotic leakage after right colon cancer surgery with stapled anastomosis. In this prospective cohort study, 535 patients who underwent right colon cancer surgery (right hemicolectomy) with stapled anastomosis were enrolled. A subset of 315 patients was included in the study after meeting the inclusion criteria. Preoperative vitamin D level was measured and analyzed for association with early AL using univariable and multivariable logistic regression analyses. This study included 315 cases; among them, 18 (5.71%) patients developed early AL. Vitamin D3 was significantly higher among patients without early AL (P < .001). Low vitamin D3 status was reported among 111 patients (35.2%) and 204 (64.8%) of patients did not have low vitamin D3 status (sufficient level = 30-100 ng/mL). Sufficient vitamin D3 levels before right colon cancer surgery with stapled anastomosis was associated inversely with early AL (crude OR = .89, 95% CI = .85-.94, P < .001 and adjusted OR = .89, 95% CI = .82-.98, P = .02). The vitamin D3 level has a protective association with early AL. As a result, low vitamin D3 status may be a risk factor for early AL development, suggesting that it can be one of the predictors of early AL occurrence.
- 30 December 2021
- Published by SAGE Publications in Surgical Innovation
- Vol. 29 (6) , 742-746
Open AccessThe Association of Vitamin D3 With Early Anastomotic Leakage in Patients Undergoing Hemicolectomy Surgery
Anastomotic leak (AL) is one of the most important postoperative complications after hemicolectomy with stapled anastomosis. This study aimed to evaluate the association of preoperative vitamin D3 with early anastomotic leakage after right colon cancer surgery with stapled anastomosis. In this prospective cohort study, 535 patients who underwent right colon cancer surgery (right hemicolectomy) with stapled anastomosis were enrolled. A subset of 315 patients was included in the study after meeting the inclusion criteria. Preoperative vitamin D level was measured and analyzed for association with early AL using univariable and multivariable logistic regression analyses. This study included 315 cases; among them, 18 (5.71%) patients developed early AL. Vitamin D3 was significantly higher among patients without early AL (P < .001). Low vitamin D3 status was reported among 111 patients (35.2%) and 204 (64.8%) of patients did not have low vitamin D3 status (sufficient level = 30-100 ng/mL). Sufficient vitamin D3 levels before right colon cancer surgery with stapled anastomosis was associated inversely with early AL (crude OR = .89, 95% CI = .85-.94, P < .001 and adjusted OR = .89, 95% CI = .82-.98, P = .02). The vitamin D3 level has a protective association with early AL. As a result, low vitamin D3 status may be a risk factor for early AL development, suggesting that it can be one of the predictors of early AL occurrence.